{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:53:03Z","timestamp":1781671983762,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Currently, all patients with American Joint Committee on Cancer (AJCC) pT2b-pT4b melanomas and a positive sentinel node biopsy are now considered for adjuvant systemic therapy without consideration of the burden of disease in the metastatic nodes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a retrospective cohort analysis of 1377 pT1-pT4b melanoma patients treated at an academic cancer center. Standard variables regarding patient, primary tumor, and sentinel node characteristics, in addition to sentinel node metastasis maximum tumor deposit size (MTDS) in millimeters and extracapsular spread (ECS) status, were analyzed for predicting disease-specific survival (DSS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The incidence of SN+ was 17.3% (238\/1377) and ECS was 10.5% (25\/238). Increasing AJCC N stage was associated with worse DSS. There was no difference in DSS between the IIIB and IIIC groups. Subgroup analyses showed that the optimal MTDS cut-point was 0.7\u00a0mm for the pT1b-pT4a SN+ subgroups, but there was no cut-point for the pT4b SN+ subgroup. Patients with MTDS &lt;0.7\u00a0mm and no ECS had similar survival outcomes as the N0 patients with the same T\u00a0stage. Nodal risk categories were developed using the 0.7\u00a0mm MTDS cut-point and ECS status. The incidence of low-risk disease, according to the new nodal risk model, was 22.3% (53\/238) in the stage III cohort, with 49% (26\/53) in the pT2b-pT3a and pT3b-pT4a subgroups and none in the pT4b subgroup. Similar outcomes were observed for overall and distant metastasis-free survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We propose a more granular classification system, based on tumor burden and ECS status in the sentinel node, that identifies low-risk patients in the AJCC IIIB and IIIC subgroups who may otherwise be observed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-022-12804-6","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T14:04:30Z","timestamp":1669730670000},"page":"1808-1819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Risk Stratification of Sentinel Node Metastasis Disease Burden and Phenotype in Stage III Melanoma Patients"],"prefix":"10.1245","volume":"30","author":[{"given":"Zahra","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Heaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Snelling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny P.","family":"Nobes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Garioch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4492-235X","authenticated-orcid":false,"given":"Marc D.","family":"Moncrieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"12804_CR1","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer Eighth Edition cancer staging manual: Melanoma Staging: AJCC 8th Edition. CA Cancer J Clin. 2017 Nov;67:472\u201392.","DOI":"10.3322\/caac.21409"},{"key":"12804_CR2","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1056\/NEJMoa060992","volume":"355","author":"DL Morton","year":"2006","unstructured":"Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307\u201317.","journal-title":"N Engl J Med."},{"key":"12804_CR3","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017;376:2211\u201322.","journal-title":"N Engl J Med."},{"key":"12804_CR4","doi-asserted-by":"crossref","unstructured":"Moncrieff MD, Lo SN, Scolyer RA, Heaton MJ, Nobes JP, Snelling AP, et al. Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease. J Clin Oncol. 2022 Jul; JCO2102488.","DOI":"10.1200\/JCO.21.02488"},{"key":"12804_CR5","unstructured":"National Institute for Health and Care Excellence (NICE). Overview, NICE Melanoma Guidelines. Melanoma: assessment and management [cited 2022 Sep 12]. Available at: https:\/\/www.nice.org.uk\/guidance\/ng14."},{"key":"12804_CR6","unstructured":"National Comprehensive Cancer Network (NCCN). Melanoma Guidelines Version 3.2022. NCCN 2022 [cited 2022 Sep 12]. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1492."},{"key":"12804_CR7","doi-asserted-by":"crossref","unstructured":"Brody T. Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines. Elsevier Science; 2016.","DOI":"10.1016\/B978-0-12-804217-5.00025-4"},{"key":"12804_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2307\/2532740","volume":"48","author":"B Lausen","year":"1992","unstructured":"Lausen B, Schumacher M. Maximally Selected Rank Statistics. Biometrics. 1992;48:73\u201385.","journal-title":"Biometrics."},{"key":"12804_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:757\u201367.","journal-title":"Lancet Oncol."},{"key":"12804_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1245\/s10434-019-07830-w","volume":"27","author":"DM Bello","year":"2020","unstructured":"Bello DM, Faries MB. The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes). Ann Surg Oncol. 2020;27:15\u201321.","journal-title":"Ann Surg Oncol."},{"key":"12804_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bjps.2019.06.020","volume":"73","author":"H Peach","year":"2020","unstructured":"Peach H, Board R, Cook M, Corrie P, Ellis S, Geh J, et al. Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement. J Plast Reconstr Aesthet Surg. 2020;73:36\u201342.","journal-title":"J Plast Reconstr Aesthet Surg."},{"key":"12804_CR12","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018;378:1789\u2013801.","journal-title":"N Engl J Med."},{"key":"12804_CR13","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","volume":"383","author":"R Dummer","year":"2020","unstructured":"Dummer R, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Kirkwood JM, et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020;383:1139\u201348.","journal-title":"N Engl J Med."},{"key":"12804_CR14","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","volume":"34","author":"GV Long","year":"2016","unstructured":"Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, et al. Overall Survival and Durable Responses in Patients With BRAF V600\u2013Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016;34:871\u20138.","journal-title":"J Clin Oncol."},{"key":"12804_CR15","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.18.01219","volume":"36","author":"A Hauschild","year":"2018","unstructured":"Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandal\u00e0 M, et al. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol. 2018;36:3441\u20139.","journal-title":"J Clin Oncol."},{"key":"12804_CR16","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, Arance A, Grob J-J, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20:1239\u201351.","journal-title":"Lancet Oncol."},{"key":"12804_CR17","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377:1824\u201335.","journal-title":"N Engl J Med."},{"key":"12804_CR18","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","volume":"21","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mandal\u00e1 M, Gogas H, Arance AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2013C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21:1465\u201377.","journal-title":"Lancet Oncol."},{"key":"12804_CR19","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635\u201348.","journal-title":"J Clin Oncol."},{"key":"12804_CR20","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR, et al. Final Version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol. 2009;27:6199\u2013206.","journal-title":"J Clin Oncol."},{"key":"12804_CR21","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1200\/JCO.2010.30.9567","volume":"28","author":"R Murali","year":"2010","unstructured":"Murali R, Desilva C, Thompson JF, Scolyer RA. Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol. 2010;28:4441\u20139.","journal-title":"J Clin Oncol."},{"key":"12804_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejso.2013.08.022","volume":"40","author":"R Feldmann","year":"2014","unstructured":"Feldmann R, Fink AM, Jurecka W, Rappersberger K, Steiner A. Accuracy of the non-sentinel node risk score (N-SNORE) in patients with cutaneous melanoma and positive sentinel lymph nodes: a retrospective study. Eur J Surg Oncol. 2014;40:73\u20136.","journal-title":"Eur J Surg Oncol."},{"key":"12804_CR23","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1245\/s10434-020-09099-w","volume":"28","author":"M Lo","year":"2021","unstructured":"Lo M, Robinson A, Wade R, Peach H, Dewar D, Heaton M, et al. Extracapsular Spread in Melanoma Lymphadenopathy: Prognostic Implications, Classification, and Management. Ann Surg Oncol. 2021;28:1642\u201353.","journal-title":"Ann Surg Oncol."},{"key":"12804_CR24","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399:1718\u201329.","journal-title":"Lancet."},{"key":"12804_CR25","unstructured":"US FDA, Center for Drug Evaluation and Research. FDA approves pembrolizumab for adjuvant treatment of Stage IIB or IIC melanoma [cited 2022 Sep 12]. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-adjuvant-treatment-stage-iib-or-iic-melanoma."},{"key":"12804_CR26","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1245\/s10434-022-11761-4","volume":"29","author":"MD Moncrieff","year":"2022","unstructured":"Moncrieff MD, Lo SN, Scolyer RA, Heaton MJ, Nobes JP, Snelling AP, et al. Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study. Ann Surg Oncol. 2022;29:5937\u201345.","journal-title":"Ann Surg Oncol."},{"key":"12804_CR27","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1200\/JCO.2004.12.177","volume":"22","author":"DJ Dewar","year":"2004","unstructured":"Dewar DJ, Newell B, Green MA, Topping AP, Powell BWEM, Cook MG. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol. 2004;22:3345\u20139.","journal-title":"J Clin Oncol."},{"key":"12804_CR28","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1200\/JCO.2010.31.6760","volume":"29","author":"APT van der Ploeg","year":"2011","unstructured":"van der Ploeg APT, van Akkooi ACJ, Rutkowski P, Nowecki ZI, Michej W, Mitra A, et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol. 2011;29:2206\u201314.","journal-title":"J Clin Oncol."},{"key":"12804_CR29","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.surg.2020.04.048","volume":"168","author":"D Han","year":"2020","unstructured":"Han D, Han G, Morrison S, Leong SP, Kashani-Sabet M, Vetto J, et al. Factors predicting survival in thick melanoma: do all thick melanomas have the same prognosis? Surgery. 2020;168:518\u201326.","journal-title":"Surgery."},{"issue":"Suppl 5","key":"12804_CR30","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1245\/s10434-016-5502-y","volume":"23","author":"DM Bello","year":"2016","unstructured":"Bello DM, Han G, Jackson L, Bulloch K, Ariyan S, Narayan D, et al. The Prognostic Significance of Sentinel Lymph Node Status for Patients with Thick Melanoma. Ann Surg Oncol. 2016;23(Suppl 5):938\u201345.","journal-title":"Ann Surg Oncol."},{"key":"12804_CR31","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1016\/j.ejca.2010.06.003","volume":"46","author":"APT van der Ploeg","year":"2010","unstructured":"van der Ploeg APT, van Akkooi ACJ, Schmitz PIM, Koljenovic S, Verhoef C, Eggermont AMM. EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria. Eur J Cancer. 2010;46:2414\u201321.","journal-title":"Eur J Cancer."},{"key":"12804_CR32","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1097\/SLA.0b013e31818fefe0","volume":"248","author":"ACJ van Akkooi","year":"2008","unstructured":"van Akkooi ACJ, Nowecki ZI, Voit C, Sch\u00e4fer-Hesterberg G, Michej W, de Wilt JHW, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg. 2008;248:949\u201355.","journal-title":"Ann Surg."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12804-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12804-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12804-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T21:43:45Z","timestamp":1675892625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12804-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["12804"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12804-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"28 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zahra Hussain, Martin J. Heaton, Andrew P. Snelling, Jenny P. Nobes, Gill Gray, Jennifer J. Garioch, and Marc D. Moncrieff have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}